Xospata 40mg Tablet (Hemifumarato de Gilteritinibe)

Xospata 40mg Tablet is an oral anticancer medicine with active ingredient Gilteritinib (40mg), targeted kinase inhibitor. It is prescribed for the treatment of acute lymphocytic leukemia (ALL), a type of blood cancer. It works by blocking the activity of specific enzyme to control the multiplication of abnormal cells & spread of cancer. It can be taken with or without food in exact dose as prescribed by the doctor.

leukemia

Like any other anticancer medicine, Xospata 40mg(Gilteritinib 40mg) Tablet also has some adverse effects on the body, and most of them are manageable without special medical attention.
Some common side effects include:
● Constipation
● Mucositis
● Edema (swelling)
● Breathlessness
● Increased transaminase level in blood
● Eye disorder
● Headache
● Dizziness
● Vomiting
● Renal impairment
● Hypotension (low blood pressure)
● Fatigue
● Joint pain
● Fever
● Rash
● Diarrhea
Seek medical attention immediately in case of any severe side effects.

Doctor determines the dosage and duration of Xospata 40mg Tablet(Gilteritinib 40mg) as per the type of disease and overall health condition of the patients. Swallow it as a whole with water. Do not chew, crush or break it. This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● Usuki, K., Sakura, T., Kobayashi, Y., Miyamoto, T., Iida, H., Morita, S., ... & Naoe, T. (2018). Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study. Cancer Science, 109(10), 3235-3244.
● Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., ... & Levis, M. J. (2019). Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. New England Journal of Medicine, 381(18), 1728-1740.
● Daver, N., Perl, A. E., Maly, J., Levis, M., Ritchie, E., Litzow, M., ... & Altman, J. K. (2022). Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology, 40(35), 4048-4059.
● Zhao, J., Song, Y., & Liu, D. (2019). Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research, 7(1), 19.
● Kantarcı, E. N., & Eşkazan, A. E. (2022). Gilteritinib in the management of acute myeloid leukemia: current evidence and future directions. Leukemia research, 114, 106808.